All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), pembrolizumab (10mg/kg) vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96]
0.74 [0.57 ; 0.96 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 360 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64]
0.50 [0.39 ; 0.64 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 360 NA not evaluable objective responses (ORR)detailed results KEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80]
8.16 [3.74 ; 17.80 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 360 NA not evaluable TRAE (any grade)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26]
0.76 [0.45 ; 1.26 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91]
0.54 [0.32 ; 0.91 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
1.92 [0.06 ; 57.48 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87]
1.65 [0.70 ; 3.87 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76]
2.73 [0.85 ; 8.76 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88]
0.05 [0.00 ; 0.88 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
0.96 [0.06 ; 15.39 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39]
0.96 [0.06 ; 15.39 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13]
2.90 [0.30 ; 28.13 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81]
1.28 [0.28 ; 5.81 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10]
0.23 [0.05 ; 1.10 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06]
3.85 [0.17 ; 86.06 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17]
0.07 [0.00 ; 1.17 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
1.92 [0.06 ; 57.48 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29]
0.48 [0.02 ; 14.29 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
0.23 [0.03 ; 2.12 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39]
0.08 [0.00 ; 1.39 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
1.92 [0.06 ; 57.48 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29]
0.24 [0.01 ; 5.29 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90]
5.81 [0.29 ; 116.90 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
0.23 [0.03 ; 2.12 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48]
1.92 [0.06 ; 57.48 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41]
0.96 [0.02 ; 48.41 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12]
0.23 [0.03 ; 2.12 ] KEYNOTE-002 (10 mg/kg), 2015 1 0% 350 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 14:41 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 575